Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1227-1236

  Pink, J J ^a   Bilimoria, M M ^b   Assikis, J ^b   Jordan, V C ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antioestrogen resistance; Breast cancer; Oestrogen receptor; Oestrogen independent growth; T47D

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; ESTROGEN DEFICIENCY; GROWTH STIMULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029844145     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.521     Document Type: Article

References (51)

1. BADLEY JE, BISHOP GA, ST JOHN T AND FRELINGER JA. (1988). A simple, rapid method for the purification of poly A RNA. Biotechniques, 6, 114 - 116.
2. BEATSON GT. (1896). On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet, 2, 162 - 165.
3. BERTHOIS Y, KATZENELLENBOGEN JA AND KATZENELLENBOGEN BS. (1986). Phenol red in tissue culture media is weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl Acad. Sci. USA, 83, 2496 - 2500.
4. BOYD S. (1990). On oophorectomy in cancer of the breast. Br. Med. J., 2, 1161-1167.
5. BROOKS SC, LOCKE ER AND SOULE HD. (1973). Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J. Biol. Chem., 248, 6251-6253.
6. BRUNNER N, BOULAY V, FOJO A, FRETER CE, LIPPMAN ME AND CLARKE R. (1993). Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res., 53, 283-290.
7. CHALBOS D, VIGNON F, KEYDAR I AND ROCHEFORT H. (1982). Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J. Clin. Endocrinol. Metab., 55, 276-283.
8. CHEN Z AND SAGER R. (1995). Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomas. Mol. Med., 1, 153-160.
9. CLARK GM, OSBORNE CK AND MCGUIRE WL. (1984). Correlations between estrogen receptor, progesterone receptor and patient characteristics in human breast cancer. J. Clin. Oncol., 2, 1102-1109.
10. CLARKE R, BRUNNER N, KATZENELLENBOGEN BS, THOMPSON EW, NORMAL MJ, KOPPI C, PAIK S, LIPPMAN ME AND DICKSON RB. (1989). Progression of human breast cancer cells from hormone-dependent to hormone-independent growth in vitro and in vivo. Proc. Natl Acad. Sci. USA, 86, 3649-3653.
11. DAFFADA AAI, JOHNSTON SRD, NICHOLLS J AND DOWSETT M. (1994). Detection of wild-type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction. J. Mol. Endocrinol., 13, 265-273.
12. DEFRIEND DJ, HOWELL A, NICHOLSON RI, ANDERSON E, DOWSETT M, MANSEL RE, BLAMEY RW, BUNDRED NJ, ROBERTSON JF, SAUNDERS C, BAUM M, WALTON P, SUTCLIFFE F AND WAKELING A. (1994). Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res., 54, 408-414.
13. DICKSON RB AND LIPPMAN ME. (1986). Hormonal control of human breast cancer cell lines. Cancer Surv., 5, 617 - 624.
14. ENCARNACION CA, CIOCCA DR, MCGUIRE WL, CLARK GM, FUQUA SA AND OSBORNE CK. (1993). Measurement of steroid hormone receptors in breast cancer patients on tumoxifen. Breast Cancer Res. Treat., 26, 237-246.
15. FERGUSON AT, LAPIDUS RG, BAYLIN SB AND DAVIDSON NE. (1995). Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res., 55, 2279-2283.
16. FERNANDEZ P, BURGHARDT R, SMITH R, NODLAND K AND SAFE S. (1994). High passage T47D human breast cancer cells: altered endocrine and 2,3,7,8-tetrachlorodibenzo-p-dioxin responsiveness. Eur. J. Pharmacol., 270, 53-65.
17. GIBSON MK, NEMMERS LA, BECKMAN WJ, DAVIS VL, CURTIS SW AND KORACH KS. (1991). The mechanisms of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology. 129, 2000-2010.
18. GRAHAM MD, KRETT NL, MILLER LA, LESLIE KK, GORDON DF, WOOD WM, WEI LL AND HORWITZ KB. (1990). T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancer to hormone resistance. Cancer Res., 50, 6208-6217.
19. HORWITZ KB AND FREIDENBERG GR. (1985). Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins: implications for endocrine therapies. Cancer Res., 45, 167-73.
20. HORWITZ KB, MOCKUS MB AND LESSEY BA. (1982). Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell. 28, 633-642.
21. HOWELL A, DEFRIEND D, ROBERTSON J, BLAMEY R AND WALTON P. (1995). Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 345, 29-30.
22. JIANG SY, WOLF DM, YINGLING JM, CHANG C AND JORDAN VC. (1992). An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol. Cell. Endocrinol., 90, 77-86.
23. JORDAN VC. (1994). The development of tamoxifen for breast cancer therapy. In Long-term Tamoxifen Treatment for Breast Cancer. Jordan VC (ed.) pp. 3-26. The University of Wisconsin Press: Madison, WI.
24. KAREY KP AND SIRBASKU DA. (1988). Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res., 48, 4083-4092.
25. KATZENELLENBOGEN BS, KENDRA KL, NORMAN MJ AND BERTHOIS Y. (1987). Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res., 47, 4355-4360.
26. KEYDAR I, CHEN L, KARBY S, WEISS FR, DELAREA J, RADU M, CHAITCIK S AND BRENNER HJ. (1979). Establishment and characterization of a cell line of human breast cancer origin. Eur. J. Cancer, 15, 659-670.
27. LABARCA C AND PAIGEN K. (1980). A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem., 102, 344-352.
28. LESLIE KK, TASSET DM AND HORWITZ KB. (1992). Functional analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells. Am. J. Obstet. Gynecol., 166, 1053-1061.
29. LIPPMAN M, BOLAN G AND HUFF K. (1976). The effects of oestrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res., 36, 4595-4601.
30. LISITSYN N, LISITSYN N AND WILGER M. (1993). Cloning the differences between two complex genomes. Science, 259, 946-951.
31. LUYTEN GP, HOOGEVEEN AT AND GALJAARD H. (1985). A fluorescence staining method for the demonstration and measurement of lysosomal enzyme activities in single cells. J. Histochem. Cytochem., 33, 965-968.
32. MACGREGOR GR AND CASKEY CT. (1989). Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Res., 17, 2365.
33. MULLICK A AND CHAMBON P. (1990). Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res., 50, 333-338.
34. MURPHY CS, MEISNER LE, WU SQ AND JORDAN VC. (1989). Short-and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur. J. Cancer Clin. Oncol., 25, 1777-1788.
35. MURPHY CS, PINK JJ AND JORDAN VC. (1990). Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res., 50, 7285-7292.
36. NARDULLI AM AND KATZENELLENBOGEN BS. (1988). Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labelling of progresterone receptor synthesis and degradation and their modulation by progestin. Endocrinology, 122, 1532-1540.
37. OSBORNE CK, CORONADO-HEINSOHN EB, HILSENBECK SG, McCUE BL, WAKELING AE, McCLELLAND RA, MANNING DL AND NICHOLSON RI. (1995). Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl Cancer Inst., 87, 746-750.
38. PARIDAENS R. (1995). Hormonal resistance in breast cancer. In Drug and Hormonal Resistance in Breast Cancer: Cellular and Molecular Mechanisms. Dickson RB and Lippman ME. (eds) pp. 21-37. Ellis Horwood: Hemel Hempstead, UK.
39. PFEFFER U, FECAROTTA E AND VIDALI G (1995). Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res., 55, 2158 - 2165.
40. PINK JJ AND JORDAN VC. (1996). Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res., 56, 2321-2330.
41. PINK JJ, JIANG SY, FRITSCH M AND JORDAN VC. (1995). An estrogen independent MCF-7 breast cancer cell line which contains a novel 80 kilodalton estrogen receptor related protein. Cancer Res., 55, 2583 - 2590.
42. PINK JJ, WU SQ, WOLF DM, BILIMORIA MM AND JORDAN VC. (1996). A novel 80 kilodalton estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res., 24, 962-969.
43. REESE CC, WARSHAW ML, MURAI JT AND SITTERI PK. (1988). Alternative models for estrogen and androgen regulation of human breast cancer cell (T47D) growth. Ann. N. Y. Acad. Sci., 538, 112-121.
44. ROBERSTON JFR. (1996). Oestrogen receptor: a stable phenotype in breast cancer. Br. J. Cancer, 73, 5-12.
45. ROBINSON SP AND JORDAN VC. (1989). The paracrine stimulation of MCF-7 cells by MDA-MBA-231 cells: possible role in antiestrogen failure. Eur. J. Cancer. Clin. Oncol., 25, 493-497.
46. SARTORIUS CA, GROSHONG SD, MILLER LA, POWELL RL, RUNG L, TAKIMOTO GS AND HORWITZ KB. (1994). New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res., 54, 3868 - 3877.
47. SOULE HD, VASQUEZ J, LONG A. ALBERT S AND BRENNAN M. (1973). A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl Cancer Inst., 51, 1409-1416.
48. WANG Y AND MIKISICEK RJ. (1991). Identification of a dominant negative form of the human estrogen receptor. Mol. Endocrinol., 5, 1707-1715.
49. WELSHONS WV AND JORDAN VC. (1987). Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur. J. Cancer Clin. Oncol., 23, 1935-1939.
50. WILDING G. LIPPMAN ME AND DICKSON RB. (1988). The cellular response of human breast cancer to estrogen. In Progress in Clinial and Biological Research, Hankins WD and Puett D (eds), 262, pp. 181-196. Alan R Liss: New York.
51. WOLF DM AND JORDAN VC. (1994). The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat., 31, 129-138.